CRISPR Therapeutics
CRISPR Therapeutics raises $337M Follow-on Offering at $8B valuation
Quick Facts
CRISPR Therapeutics: Follow-on Offering Funding Round
CRISPR Therapeutics has successfully raised $337M in Follow-on Offering funding, reaching a valuation of $8B.
Company Overview
Gene-based medicines using CRISPR/Cas9
Funding Details
The Follow-on Offering round was led by Versant Ventures, with participation from Bayer, Vertex Pharmaceuticals.
Company Information
- Headquarters: Aeschenvorstadt 36, Basel 4051, Switzerland
- Founded: 2013
- Employees: 500+
- Category: Biotech
Investment
CRISPR Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Versant Ventures: Verified investor in Follow-on Offering
- Bayer: Verified investor in Follow-on Offering
- Vertex Pharmaceuticals: Verified investor in Follow-on Offering
Key Investors
About the Author

Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...

Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...

Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
